Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

105 recalls · Class I, newest first

Class I · High risk

Morphine Sulfate Injection

Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.

Ongoing Labeling / mix-up Fresenius Kabi USA, LLC D-0788-2026
Class I · High risk

Magnesium Sulfate in Water for Injection

Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.

Ongoing Labeling / mix-up Amneal Pharmaceuticals, LLC NDC 70121-1720-3 D-0478-2026
Class I · High risk

POTASSIUM CHLORIDE Inj.

Labeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj. 20 mEq

Ongoing Labeling / mix-up Otsuka ICU Medical LLC NDC 0990-7074-26 D-0181-2026
Class I · High risk

POTASSIUM CHLORIDE Inj.

Labeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj. 20 mEq

Ongoing Labeling / mix-up Otsuka ICU Medical LLC NDC 0990-7077-14 D-0180-2026
Class I · High risk

Cyclobenzaprine Hydrochloride Tablets

Labeling: Label Mix Up; Bottles of Meloxicam USP, 7.5mg, 90-count tablets (yellow in color), were labeled as Cyclobenzaprine Hydrochloride Tablets USP, 10 mg 90-count tablets (blue in color).

Ongoing Labeling / mix-up Unichem Pharmaceuticals USA Inc. NDC 29300-415-19 D-0655-2025
Class I · High risk

Cefazolin for Injection

Labeling: Label Mix-Up; cartons of Cefazolin for Injection, USP 1 gram were found to contain vials labeled as penicillin G potassium for Injection, USP, 20 million Unit. The vials contained Cefozalin

Ongoing Labeling / mix-up Sandoz Inc D-0569-2025
Class I · High risk

Levetiracetam 0.75% in Sodium Chloride Injection 1

LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

Ongoing Labeling / mix-up Dr. Reddy's Laboratories, Inc. NDC 43598-636-52 D-0365-2025
Class I · High risk

POTASSIUM CHLORIDE Inj.

Labeling: Label Error on Declared Strength. Overwrap labeled as Potassium Chloride Inj 10 mEq may contain flexible containers of Potassium Chloride Inj 20 mEq

Ongoing Labeling / mix-up ICU Medical, Inc. NDC 0990-7074-26 D-0268-2025
Class I · High risk

POTASSIUM CHLORIDE Inj.

Labeling: Label Error on Declared Strength. Cases labeled POTASSIUM CHLORIDE 20 mEq, may contain flexible containers with overwrap mislabeled as 10 mEq. The correct dosage strength of 20 mEq is printed on the labeling affixed to the product flexible container.

Ongoing Labeling / mix-up ICU Medical, Inc. NDC 0990-7075-26 D-0267-2025
Class I · High risk

Adrenalin Chloride Solution

Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin¿ (epinephrine injection, USP)

Ongoing Labeling / mix-up ENDO USA, Inc. NDC 42023-103-01 D-0223-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0181-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0180-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0179-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablet

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0178-2025
Class I · High risk

Healthy Living Acetaminophen

Labeling: Missing Label - some bottles are missing the the manufacturers label that includes the drug facts information.

Ongoing Labeling / mix-up Aurobindo Pharma USA Inc NDC 58602-882-21 D-0641-2024
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled as 0.125 mg instead of 0.25 mg. The blister strips inside the product carton reflect the correct strength of 0.25 mg.

Terminated Labeling / mix-up Endo Pharmaceuticals, Inc. NDC 49884-306-02 D-0622-2024
Class I · High risk

Acetaminophen Injection

Labeling: Label Mix-up: a bag of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection was found inside an overwrap labeled Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL)

Ongoing Labeling / mix-up Hikma Pharmaceuticals USA Inc. NDC 0143-9386-01 D-0635-2024
Class I · High risk

Acetaminophen Extra Strength Tablets

Labeling: Label Mix-Up: Some bottles of Acetaminophen Extra Strength 500 mg tablets were incorrectly labeled with the drug facts label for Aspirin 81 mg tablets.

Terminated Labeling / mix-up A-S Medication Solutions LLC D-0631-2024
Class I · High risk

Digoxin Tablets

Labeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets, USP 0.25mg contain Digoxin Tablets, USP 0.125mg.

Terminated Labeling / mix-up Marlex Pharmaceuticals, Inc. NDC 10135-0747-01 D-1169-2023
Class I · High risk

ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg

Labeling: Label Mix-up: Unit Dose cartons labeled as Ziprasidone Hydrochloride Capsules, 20 mg were found to contain blister packages labeled as and containing Dronabinol Capsules, USP, 2.5 mg.

Terminated Labeling / mix-up The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-6269-08 D-0893-2023
Class I · High risk

G-Supress DX

Product mix-up: incorrect product was found inside the G-Supress DX product carton.

Terminated Labeling / mix-up Novis PR, LLC dba Kramer Novis NDC 52083-655-01 D-0868-2023

Recalls by year